Results 71 to 80 of about 106,528 (297)

Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?

Dermatology Practical & Conceptual
Introduction: Tildrakizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown promise in the management of moderate-to-severe plaque psoriasis, offering potential improvements in clinical outcomes and ...
Eugenia Veronica Di Brizzi, Stefano Caccavale, Roberta Di Caprio, Francesco Cusano, Rocco De Pasquale , Valeria Falcomatà, Caterina Foti, Claudia Giofrè, Emanuela Gubinelli, Giampiero Mazzocchetti, Massimiliano Nicolini, Giovanni Palazzo, Leonardo Pescitelli, Rosa Valentina Puca, Oriele Sarno, Anna Balato   +15 more
doaj   +1 more source

The Impact of Nonsteroidal Anti‐Inflammatory Drugs on Radiographic Spinal Progression in Patients With Axial Spondyloarthritis: 10‐Year Results From an Inception Cohort

Arthritis &Rheumatology, EarlyView.
Objective This study aims to investigate the impact of nonsteroidal anti‐inflammatory drug (NSAID) intake on radiographic spinal progression in axial spondyloarthritis (axSpA), considering different NSAID types (COX‐2 inhibitors [COX2i] and nonselective NSAIDs [ns‐NSAIDs]) and disease subgroups (radiographic [r‐axSpA] and nonradiographic [nr‐axSpA ...
Murat Torgutalp, Valeria Rios Rodriguez, Fabian Proft, Mikhail Protopopov, Judith Rademacher, Hildrun Haibel, Joachim Sieper, Martin Rudwaleit, Denis Poddubnyy   +8 more
wiley   +1 more source

Traditional Systemic Treatment of Psoriasis

The Journal of Rheumatology Supplement, 2009
Psoriasis is an inflammatory skin disease with a chronic relapsing course. In about 20%-30% of psoriatic patients, disease severity requires systemic treatment, which carries a huge economic and management burden for the healthcare system. The decision to employ systemic treatment, reserved for severe or extensive forms, needs to be weighed carefully ...
G.F. Altomare, A. Altomare, P.D. Pigatto
openaire   +3 more sources

Serious Infections in Offspring Exposed to Tumor Necrosis Factor Inhibitors During Pregnancy: Comparison of Timing During Pregnancy and Placental Transfer Ability

Arthritis &Rheumatology, EarlyView.
Objective We evaluated serious infection risk in offspring exposed to tumor necrosis factor inhibitors (TNFi) in utero, separated by TNFi timing and placental transfer ability. Methods Using MarketScan (2011–2021), we identified offspring born to mothers with chronic inflammatory diseases.
Leah K. Flatman, Sasha Bernatsky, Yvan St‐Pierre, Marie‐Eve Beauchamp, Isabelle Malhamé, Anick Bérard, Évelyne Vinet   +6 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

Measuring the Impact: MRI Response of Sacroiliac Joints to TNF Inhibitors in Youth with Axial Disease

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes in youth with axial juvenile spondyloarthritis (axJSpA) initiating TNF inhibitor (TNFi).
Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss   +8 more
wiley   +1 more source

Topical therapies in psoriasis

Indian Dermatology Online Journal, 2017
Topical therapy as monotherapy is useful in psoriasis patients with mild disease. Topical agents are also used as adjuvant for moderate-to-severe disease who are being concurrently treated with either ultraviolet light or systemic medications. Emollients
R Torsekar, Manjyot M Gautam
doaj   +1 more source

A New Era for Using Natural Pigments: The Case of the C50 Carotenoid Called Bacterioruberin

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Haloarchaea are extremophilic microorganisms belonging to the Archaea domain that require high salt concentrations to live, thus inhabiting ecosystems like salty ponds, salty marshes, or extremely salty lagoons. They are more abundant and widely distributed worldwide than initially expected.
Micaela Giani, Elena Valdés, José María Miralles‐Robledillo, Guillermo Martínez, Carmen Pire, Rosa María Martínez‐Espinosa   +5 more
wiley   +1 more source

Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis)

Frontiers in Immunology
IntroductionThe development of several effective biological drugs for moderate-to-severe plaque psoriasis has dramatically changed the lives of patients.
Luigi Gargiulo, Luigi Gargiulo, Luciano Ibba, Luciano Ibba, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Giovanni Damiani, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo V. Marzano, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Santo R. Mercuri, Massimo Travaglini, Antonio Costanzo, Antonio Costanzo, Alessandra Narcisi   +26 more
doaj   +1 more source

Design, Synthesis, and Biological Evaluation of an Orally Bioavailable, Potent, and Selective ROCK2 Inhibitor for Psoriasis Treatment

, 2023
Yun Huang, Chu-Ru Mao, Yijie Lou, Shuai Zhan, Zhe Chen, Wanjing Ding, Zhongjun Ma   +6 more
openalex   +1 more source